Sign In
Buy RHHBY
$54.64
-0.630 (-1.14%)
At Close: Jul 31, 2026
Genentech's Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS
07:15pm, Tuesday, 21'st Apr 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today new data from the positive Phase III FENhance 1 and 2 studies, which
Roche's fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS
07:15pm, Tuesday, 21'st Apr 2026
Basel, 22 April 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today new data from the positive Phase III FENhance 1 and 2 studies, which met their primary endpoint. The studies showed that feneb
Genentech's Enspryng (Satralizumab) Reduces Risk of Relapses by 68% Demonstrating Potential to Become First Treatment for MOGAD
11:45am, Tuesday, 21'st Apr 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today new data from the Phase III METEOROID study demonstrating that Enspry
Roche's ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD
11:45am, Tuesday, 21'st Apr 2026
Basel, 21 April 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today new data from the Phase III METEOROID study demonstrating that ENSPRYNG® (satralizumab) reduced the risk of a new relapse by
FDA accepts application for Roche’s Gazyva/Gazyvaro for the treatment of the most common form of lupus
01:00am, Tuesday, 21'st Apr 2026
Filing acceptance based on phase III ALLEGORY data for Gazyva/Gazyvaro showing a significant reduction in disease activity compared with placebo in people with systemic lupus erythematosus (SLE) If ap
FDA accepts application for Roche's Gazyva/Gazyvaro for the treatment of the most common form of lupus
01:00am, Tuesday, 21'st Apr 2026
Basel, 21 April 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) fo
FDA Accepts Application for Genentech's Gazyva for the Treatment of the Most Common Form of Lupus
01:00am, Tuesday, 21'st Apr 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the US Food and Drug Administration (FDA) has accepted the compa
Roche launches new Elevidys study after feedback from European regulator
07:25am, Thursday, 16'th Apr 2026
Roche on Thursday said it is initiating a late stage study for its gene therapy Elevidys following feedback from the European drug regulator. The therapy for duchenne muscular dystrophy (DMD), f
Roche receives CE mark for new Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis
01:00am, Monday, 13'th Apr 2026
Basel, 13 April 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that its Elecsys® Neurofilament Light Chain (NfL) test has received CE mark approval for the detection of neuroinflammation i
C4 Therapeutics, Roche expand partnership with new cancer deal worth over $1 billion
09:34am, Thursday, 09'th Apr 2026
C4 Therapeutics said on Thursday it has entered into a deal focused on research and development of a type of cancer drug with Swiss drugmaker Roche that could be worth more than $1 billion.
Agreement Focused on Developing DACs With Payloads For Two Oncology Targets, With an Option for a Third Target C4T to Develop Degraders With Payload Properties; Roche to Conjugate Payloads to Targeted
Market Today: Ceasefire Rally, Meta AI Launch, Deere Deal
06:53pm, Wednesday, 08'th Apr 2026
Stock News Oil slumps, stocks jump on truce: Global crude prices tumbled (Brent briefly under $92) and equities rallied after a conditional U.S.-Iran two-week c
First Look: Ceasefire Rally, Delta Beats, UMG Bid, AI Jobs
07:37am, Wednesday, 08'th Apr 2026
Stock News Futures jump on Iran truce: U.S. equity futures surged and oil tumbled after a two-week U.S.âIran ceasefire, with airlines like Delta Air Lines (DA
Market Today: Oil Shock, Airline Moves, UMG Bid, LEVI Beat
05:33pm, Tuesday, 07'th Apr 2026
Guru Stock PicksBrandes Investment Partners, LP has made the following transactions:Add in KMT by 0.94%Stock News Stocks steady into Iran deadline: The S&P 500
HNL Lab Medicine Celebrates Preferred Partnership With Roche Diagnostics
09:42am, Tuesday, 07'th Apr 2026
ALLENTOWN, Pa., April 07, 2026 (GLOBE NEWSWIRE) -- HNL Lab Medicine today announced a preferred partnership with Roche Diagnostics.
